Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 25;52(48):12572-6.
doi: 10.1002/anie.201304465. Epub 2013 Oct 9.

PEGylation and zwitterionization: pros and cons in the renal clearance and tumor targeting of near-IR-emitting gold nanoparticles

Jinbin Liu  1 , Mengxiao Yu, Xuhui Ning, Chen Zhou, Shengyang Yang, Jie Zheng
Affiliations

PEGylation and zwitterionization: pros and cons in the renal clearance and tumor targeting of near-IR-emitting gold nanoparticles

Jinbin Liu et al. Angew Chem Int Ed Engl. .
No abstract available

Keywords: PEGylation; nanoparticles; renal clearance; surface chemistry; tumor targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characterization of NIR-emitting PEGylated AuNPs (PEG-AuNPs). a) Scheme of the particle synthesis. b) Typical TEM image of the synthesized PEG-AuNPs. c) The core size measured by TEM, and hydrodynamic diameter (HD) of PEG-AuNPs in PBS measured by dynamic light scattering (DLS). d) Absorption and luminescent spectra of PEG-AuNPs in PBS at pH 7.4.
Figure 2
Figure 2
Biodistribution analysis of the passive tumor targeting in MCF-7 tumor-bearing mice. a) The biodistributions of PEG-AuNPs at 1, 12, 24, and 48 h p.i.. b) The time-dependent ratios of PEG-AuNPs concentration in tumor to that in liver within 48 h p.i. (Inset: a comparison of PEG-AuNPs and GS-AuNPs in tumor/liver ratios at 1, 12, and 24 h p.i.). c) The time-dependent tumor/blood ratios of PEG-AuNPs within 48 h p.i. (Inset: a comparison of the two probes in tumor/blood ratios at 1, 12, and 24 h p.i.). d) Pharmacokinetics of these two probes after intravenous (IV) injection (Data presented as mean ± SD, n = 3).
Figure 3
Figure 3
Passive tumor-targeting kinetics of PEG-AuNPs in MCF-7 tumor bearing nude mice. a) In vivo NIR fluorescence images of the mouse IV injected with PEG-AuNPs at 5, 12, 18, 24, and 48 h p.i. (arrow: tumor location). b) Time-dependent contrast index (CI) of tumor area after IV injection of PEG-AuNPs and GS-AuNPs, respectively. c) Accumulation and retention kinetics of PEG-AuNPs in tumor and normal tissues.
Figure 4
Figure 4
Renal clearance kinetics of PEG-AuNPs in nude mice. a) In vivo NIR fluorescence images of the nude mouse IV injected with PEG-AuNPs collected at 2, 3, and 4 h p.i. (circle: bladder area). b) Renal clearance kinetics of PEG-AuNPs and GS-AuNPs (Inset: PEG-AuNPs found in the urine measured by ICP-MS 12 and 24 h p.i.).
See this image and copyright information in PMC

Comment in

References

    1. Wang Y, Liu Y, Luehmann H, Xia X, Brown P, Jarreau C, Welch M, Xia Y. Acs Nano. 2012;6:5880–5888. - PMC - PubMed
    2. Chen JY, Glaus C, Laforest R, Zhang Q, Yang MX, Gidding M, Welch MJ, Xia YN. Small. 2010;6:811–817. - PMC - PubMed
    3. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanomedicine-Uk. 2011;6:715–728. - PMC - PubMed
    4. Della Rocca J, Huxford RC, Comstock-Duggan E, Lin WB. Angew. Chem. Int. Edit. 2011;50:10330–10334. - PMC - PubMed
    5. Matsumura Y, Maeda H. Cancer Res. 1986;46:6387–6392. - PubMed
    6. Iyer AK, Khaled G, Fang J, Maeda H. Drug Discov. Today. 2006;11:812–818. - PubMed
    7. Hong H, Zhang Y, Sun J, Cai W. Nano Today. 2009;4:399–413. - PMC - PubMed
    1. Kommareddy S, Amiji M. J. Pharm. Sci. 2007;96:397–407. - PubMed
    2. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Mol. Pharmaceut. 2008;5:505–515. - PMC - PubMed
    1. Schipper ML, Iyer G, Koh AL, Cheng Z, Ebenstein Y, Aharoni A, Keren S, Bentolila LA, Li JQ, Rao JH, Chen XY, Banin U, Wu AM, Sinclair R, Weiss S, Gambhir SS. Small. 2009;5:126–134. - PMC - PubMed
    1. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Adv. Drug Deliv. Rev. 2009;61:457–466. - PMC - PubMed
    2. Dobrovolskaia MA, McNeil SE. Nat. Nanotechnol. 2007;2:469–478. - PubMed
    3. Kareem H, Sandstrom K, Elia R, Gedda L, Anniko M, Lundqvist H, Nestor M. Tumour Biol. 2010;31:79–87. - PubMed
    1. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. PLoS One. 2011;6:e24374. - PMC - PubMed

Publication types